Responses

Download PDFPDF

BRCA1 c.2845insA is a recurring mutation with a founder effect in Singapore Malay women with early onset breast/ovarian cancer
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Recurrent BRCA1 mutation among Malay breast/ovarian cancer patients
    • Ann SG Lee, Senior Scientist
    • Other Contributors:
      • Gay-Hui Ho

    Dear Editor

    We read with great interest the report by Sng et al. [1] in which the authors reported that the BRCA1 frameshift mutation 2845insA could be a founder mutation in Malay breast or ovarian cancer patients in Singapore. This mutation results in protein truncation at codon 914.

    We would like to take this opportunity to draw the readers’ attention to our work on BRCA1 mutations among Singapo...

    Show More
    Conflict of Interest:
    None declared.